A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Filgotinib (Primary) ; GS 9876 (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 20 Jun 2017 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.
- 20 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2018.
- 31 May 2017 Status changed from not yet recruiting to recruiting.